Directional migration of mesenchymal stem cells under an SDF-1 alpha gradient on a microfluidic device
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Siwan | - |
dc.contributor.author | Jang, Hwanseok | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Hwang, Changmo | - |
dc.contributor.author | Jeong, Gi Seok | - |
dc.contributor.author | Park, Yongdoo | - |
dc.date.accessioned | 2021-09-03T01:50:32Z | - |
dc.date.available | 2021-09-03T01:50:32Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-09-08 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/82254 | - |
dc.description.abstract | Homing of peripheral stem cells is regulated by one of the most representative homing factors, stromal cell-derived factor 1 alpha (SDF-1 alpha), which specifically binds to the plasma membrane receptor CXCR4 of mesenchymal stem cells (MSCs) in order to initiate the signaling pathways that lead to directional migration and homing of stem cells. This complex homing process and directional migration of stem cells have been mimicked on a microfluidic device that is capable of generating a chemokine gradient within the collagen matrix and embedding endothelial cell (EC) monolayers to mimic blood vessels. On the microfluidic device, stem cells showed directional migration toward the higher concentration of SDF-1 alpha, whereas treatment with the CXCR4 antagonist AMD3100 caused loss of directionality of stem cells. Furthermore, inhibition of stem cell's main migratory signaling pathways, RhoROCK and Rac pathways, caused blockage of actomyosin and lamellipodia formation, decreasing the migration distance but maintaining directionality. Stem cell homing regulated by SDF-1 alpha caused directional migration of stem cells, while the migratory ability was affected by the activation of migration-related signaling pathways. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.subject | CHEMOKINE RECEPTOR CXCR4 | - |
dc.subject | ENDOTHELIAL-CELLS | - |
dc.subject | PROSTATE-CANCER | - |
dc.subject | RHO-GTPASES | - |
dc.subject | METASTASIS | - |
dc.subject | INHIBITOR | - |
dc.subject | MICE | - |
dc.subject | CHEMOTAXIS | - |
dc.subject | ACTIVATION | - |
dc.subject | PLATFORM | - |
dc.title | Directional migration of mesenchymal stem cells under an SDF-1 alpha gradient on a microfluidic device | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yongdoo | - |
dc.identifier.doi | 10.1371/journal.pone.0184595 | - |
dc.identifier.scopusid | 2-s2.0-85029389515 | - |
dc.identifier.wosid | 000410001100164 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.12, no.9 | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 12 | - |
dc.citation.number | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | CHEMOKINE RECEPTOR CXCR4 | - |
dc.subject.keywordPlus | ENDOTHELIAL-CELLS | - |
dc.subject.keywordPlus | PROSTATE-CANCER | - |
dc.subject.keywordPlus | RHO-GTPASES | - |
dc.subject.keywordPlus | METASTASIS | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordPlus | CHEMOTAXIS | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | PLATFORM | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.